| Autor: |
Bianca Serio, Francesco Grimaldi, Lucia Ammirati, Mario Annunziata, Giovanna De Santis, Alessandra Perrotta, Danilo De Novellis, Valentina Giudice, Denise Morini, Gabriella Storti, Catello Califano, Antonio Maria Risitano, Fabrizio Pane, Carmine Selleri |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2573-8348 |
| DOI: |
10.1002/cnr2.2044 |
| Popis: |
Abstract Background Gemtuzumab‐ozogamycin (GO) is approved in combination with high‐dose chemotherapy for treatment‐naïve low‐ and intermediate‐risk acute myeloid leukemia (AML). Aims In this retrospective real‐life multicenter study, we reported efficacy and safety of GO plus high‐dose chemotherapy in newly diagnosed AML patients. Methods and Results A total of 31 fit low‐ and intermediate‐risk AML patients treated with GO‐based regimens were retrospectively included in this real‐life multicenter study, and results were compared with a control cohort treated with 3 + 7 alone. Complete remission (CR) rate after induction was 77%, and most responders (45%) underwent two GO‐based consolidation, and minimal residual disease (MRD) negativity was observed in 17 cases (55%) after the end of consolidation. Low genetic risk was associated with increased CR rate compared with intermediate‐risk AML (88% vs. 33%; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text